Project Description
- Speciality: Oncology – Medical
- Clinic: Mount Elizabeth Novena Hospital
Background
- Dokter senior yang sudah berpengalaman di bidangnya
- Keahlian khusus pada breast cancer
- Dr Tan Sing Huang was a senior consultant in the Department of Haematology-Oncology at the National University Cancer Institute, Singapore (NCIS). There, she led the Senior Residency Education division as its programme director, and was co-chairman of their clinical competency committee for Senior Residency training.
- For her contributions to education at the National University Hospital (NUH), Dr Tan was awarded the NUH Teaching Excellence Award in 2014. She was also an assistant professor at the Yong Loo Lin School of Medicine, National University of Singapore, and participated as an examiner for undergraduate final medical exams.
- Dr Tan is the current vice president of the Singapore Society of Oncology. She is also a longstanding active committee member of the National Healthcare Group’s Domain-Specific Ethics Review Board since 2011, and is a workgroup member for the College of Radiologists’ National Breast Cancer Screening Guidelines Review for 2017.
- She also served as the chairman of conferences like the Best of ASCO in 2015, and was the co-organiser of the inaugural Breast Day Symposium in 2016.
- Dr Tan has obtained a number of independent grants since 2008, studying areas such as methylation patterns in breast cancer, high-throughput oncogenic mutation profiling in breast cancers, chemotherapeutic regimens and clinical outcomes, and the effects of chemotherapy on cognition in cancer patients using PET scan imaging.
- Dr Tan has been invited to write chapters on chemotherapy treatment of metastatic breast cancer in the renowned international textbook Diseases of the Breast.
- She has also written several articles published in international journals on topics such as the use of ovarian suppression in breast cancer, high-throughput mutation profiling changes before and after chemotherapy, tumour gene expression profiling, and pharmacogenetics in breast cancers.